Yahoo
Toronto - Free Realtime Quote CAD

COSCIENS Biopharma Inc. (CSCI.TO)

8.50 +0.10 (+1.19%)
As of 10:55:04 AM EST. Market Open.
View in AlphaSpace Currency in USD All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
8,725
7,498
9,587
7,143
14,572
Cost of Revenue
4,670
4,851
4,858
4,205
6,016
Gross Profit
4,055
2,647
4,729
2,938
8,556
Operating Expense
10,185
13,012
18,752
7,567
4,236
Operating Income
-6,130
-10,365
-14,023
-4,629
4,320
Net Non Operating Interest Income Expense
-47
115
312
-77
2
Other Income Expense
390
-98
-1,514
336
206
Pretax Income
-5,787
-10,348
-15,225
-4,370
4,528
Tax Provision
8
10
84
-885
1,080
Net Income Common Stockholders
6,553
-10,358
-15,309
-3,485
3,448
Diluted NI Available to Com Stockholders
6,553
-10,358
-15,309
-3,485
3,448
Basic EPS
6.32
-9.81
-17.79
-5.67
5.61
Diluted EPS
4.77
-9.81
-17.79
-5.67
5.58
Basic Average Shares
1,053.59
1,055.10
860.44
615.74
613.30
Diluted Average Shares
1,149.08
1,055.10
860.44
615.74
618.18
Total Operating Income as Reported
--
-10,681
-18,280
-4,629
4,320
Total Expenses
14,855
17,863
23,610
11,772
10,252
Net Income from Continuing & Discontinued Operation
6,553
-10,358
-15,309
-3,485
3,448
Normalized Income
-6,008.60
-10,259.55
-14,115.80
-3,465.86
3,287.33
Interest Income
140
283
441
59
145
Interest Expense
187
168
129
136
143
Net Interest Income
-47
115
312
-77
2
EBIT
-5,600
-10,180
-15,096
-4,234
4,671
EBITDA
-4,346
-8,992
-13,489
-2,791
6,139
Reconciled Cost of Revenue
4,670
4,851
4,858
4,205
6,016
Reconciled Depreciation
1,254
1,188
1,607
1,443
1,468
Net Income from Continuing Operation Net Minority Interest
-5,795
-10,358
-15,309
-3,485
3,448
Total Unusual Items Excluding Goodwill
356
-133
-1,612
-24
211
Total Unusual Items
356
-133
-1,612
-24
211
Normalized EBITDA
-4,702
-8,859
-11,877
-2,767
5,928
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
142.40
-34.55
-418.80
-4.86
50.33
12/31/2022 - 9/18/1996

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: